Condition
Therapeutic Vaccine
Total Trials
2
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
4 treatments under study, led by Hivmag Pdna
Research Leaders
5 sponsors active, led by National Institute of Allergy and Infectious Diseases (NIAID)
Related Conditions
Often studied with 5 related conditions
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
Phase 1 (1)
Phase 4 (1)
Trial Status
Completed2
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
Research Network
Common Treatments
- Hivmag Pdna1
- Il12 Pdna Adjuvant1
- Rvsv1
- Bcg1
Active Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)1
- Auro Vaccines LLC1
- Paulínia Municipal Hospital1
- Conselho Nacional de Desenvolvimento Científico e Tecnológico1
- University of Campinas, Brazil1
Top Investigators
UroScience, University of Campinas
National Institute of Allergy and Infectious Diseases (NIAID)
Related Conditions
- Bcg1
- Hiv1
- Sarscov 21
- Covid191
- Transmission1